Extragastrointestinal Stromal Tumors Presenting as Vulvovaginal/Rectovaginal Septal Masses
- 1 July 2006
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in International Journal of Gynecological Pathology
- Vol. 25 (3), 288-292
- https://doi.org/10.1097/01.pgp.0000215291.22867.18
Abstract
Gastrointestinal stromal tumor (GIST) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Most GISTs arise in the stomach and small bowel, whereas a small number occur elsewhere in the GI tract. Rare cases are identified outside the GI tract and are collectively known as extragastrointestinal stromal tumors (EGISTs). Because of their malignant potential and recent advances in the management of GISTs with imatinib mesylate (Gleevec, Glivec), it is imperative that these tumors are correctly diagnosed. In this study, we reviewed the clinical and pathologic characteristics of 3 cases of EGIST presenting as vulvovaginal/rectovaginal septal masses that were originally misdiagnosed, presumably due to their unusual anatomic locations. The original diagnoses were leiomyoma in one case and leiomyosarcoma in 2 cases. The lesions were localized to the rectovaginal septum () or vagina () and ranged from 4 to 8 cm in diameter. All 3 lesions had a spindle cell morphology that mimicked a smooth muscle tumor. Mitotic figures numbered from 12/50 to 16/50 high power fields (HPFs; median 15). Immunohistochemistry revealed that all 3 cases were strongly positive for KIT (CD117) and CD34 and negative for smooth muscle actin, desmin, pan-cytokeratin, and estrogen receptor. KIT sequence analysis revealed oncogenic mutations in all 3 cases. The first tumor recurred at 2 years and the second tumor recurred at 10 years; the third case is too recent for meaningful follow-up. EGISTs that present as gynecologic masses are rare but may be more common than is currently recognized. Misdiagnosis may lead to inappropriate therapy because conventional chemotherapy and radiotherapy are not effective in the treatment of GISTs, whereas imatinib mesylate (Gleevec, Glivec) has a proven role in managing these tumors. Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum.Keywords
This publication has 20 references indexed in Scilit:
- Gastrointestinal Stromal Tumor Presenting as a Recurrent Vaginal MassArchives of Pathology & Laboratory Medicine, 2004
- Gastrointestinal stromal tumor arising in the rectovaginal septumInternational Journal of Gynecologic Cancer, 2004
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in SizeThe American Journal of Pathology, 2002
- Diagnosis of gastrointestinal stromal tumors: A consensus approachHuman Pathology, 2002
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of OutcomeLaboratory Investigation, 2000
- Gastrointestinal stromal tumors: Recent advances in understanding of their biologyHuman Pathology, 1999
- Superiority of Denaturing High Performance Liquid Chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2Annals of Human Genetics, 1999